SQUAWK/NEWS
Account
Theme
Account
Menu
Live News NEWS FLASH L impact

Celea Therapeutics Presents SURPASS-IPF Phase 3 Trial Design and Statistical Considerations for Evaluating Clinical Trials in Idiopathic Pulmonary Fibrosis at the IPF Summit 2026

Celea Therapeutics, Inc. ("Celea" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for serious respiratory diseases with significant unmet medical need, today announced that the Company will deliver two poster presentations showcasing its…

Related stories